OCGN Ocugen, Inc. Stock Quote

OCGN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.25	Insider Own	0.80%	Shs Outstand	198.79M	Perf Week	-21.88%
Market Cap	717.75M	Forward P/E	12.16	EPS next Y	0.27	Insider Trans	-44.23%	Shs Float	193.85M	Perf Month	-35.41%
Income	-47.60M	PEG	-	EPS next Q	-0.07	Inst Own	29.90%	Short Float	28.48%	Perf Quarter	-60.10%
Sales	-0.00M	P/S	-	EPS this Y	79.00%	Inst Trans	5.93%	Short Ratio	1.83	Perf Half Y	-51.32%
Book/sh	0.54	P/B	6.15	EPS next Y	193.10%	ROA	-59.10%	Target Price	8.88	Perf Year	59.62%
Cash/sh	0.50	P/C	6.69	EPS next 5Y	-	ROE	-65.30%	52W Range	1.40 - 18.77	Perf YTD	-27.03%
Dividend	-	P/FCF	-	EPS past 5Y	70.80%	ROI	-	52W High	-82.21%	Beta	4.63
Dividend %	-	Quick Ratio	18.20	Sales past 5Y	-	Gross Margin	-	52W Low	138.57%	ATR	0.42
Employees	15	Current Ratio	18.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	30.86	Volatility	10.04% 9.60%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	26.90%	Profit Margin	-	Rel Volume	0.16	Prev Close	3.32
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Nov 09 BMO	Payout	-	Avg Volume	30.16M	Price	3.34
Recom	2.50	SMA20	-20.44%	SMA50	-39.29%	SMA200	-55.61%	Volume	3,332,460	Change	0.60%

Jul-26-21

Initiated

Noble Capital Markets

Outperform

Jun-11-21

Downgrade

ROTH Capital

Buy → Neutral

$10 → $6

May-07-21

Downgrade

Cantor Fitzgerald

Overweight → Neutral

Feb-09-21

Downgrade

Chardan Capital Markets

Buy → Neutral

$0.70 → $13

Feb-04-21

Upgrade

H.C. Wainwright

Neutral → Buy

$4.50

Jan-24-22 09:44AM	Ocugen, Inc. (NASDAQ:OCGN) Could Be Less Than A Year Away From Profitability Simply Wall St.
07:12AM	Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety GlobeNewswire
Jan-21-22 06:12PM	Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -7.87%
Jan-20-22 04:35PM	Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week Motley Fool
10:30AM	Is Ocugen Stock a Buy Now? Motley Fool
Jan-19-22 01:51PM	7 Robinhood Stocks You Can Still Buy for Under $5 InvestorPlace -6.75%
Jan-14-22 11:19AM	In Search of a Better Covid Vaccine, This Analyst Taps Ocugen TipRanks +5.72%
06:00AM	Can the Faithful Provide a Lifeline to Ocugen? InvestorPlace
Jan-13-22 10:29AM	Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron Zacks
Jan-12-22 05:33PM	Why Ocugen Stock Couldn't Outrun the Market Today Motley Fool
11:13AM	OCGN Stock Alert: Why Is Ocugen Soaring 10% Today? InvestorPlace
06:43AM	COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2 GlobeNewswire
Jan-11-22 07:47AM	Better Vaccine Stock: Ocugen vs. Inovio Pharmaceuticals Motley Fool
Jan-10-22 09:08AM	OCGN Stock Alert: Why Is Ocugen Gaining Today? InvestorPlace +6.40%
07:26AM	Ocugen's stock gains 8% on promising COVID-19 booster data from partner Bharat Biotech MarketWatch
05:40AM	Ocugen Reveals Data From Bharat Biotech Partnered Covaxin Booster Dose Benzinga
Jan-08-22 06:27PM	COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety GlobeNewswire
Jan-07-22 02:35PM	The Top 3 Robinhood Stocks of 2021 InvestorPlace
06:00AM	Could Ocugen Become the Next Moderna? Motley Fool
Jan-06-22 06:03PM	Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference GlobeNewswire
Jan-04-22 11:59AM	Why Pfizer, Novavax, and Ocugen Stocks Are Sinking Today Motley Fool -5.30%
Dec-31-21 10:01PM	Why Ocugen Sank Friday After Soaring Thursday Motley Fool -5.80%
08:27AM	Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group Zacks
05:57AM	10 Top Robinhood Stocks That Doubled in 2021: Are They Buys Now? Motley Fool
05:56AM	Why Co-Diagnostics, Ocugen, and Sorrento Stocks Are Sinking This Week Motley Fool
Dec-30-21 07:09PM	Why Ocugen Trounced the Market on Thursday Motley Fool +10.27%
12:45PM	Daily average of COVID-19 cases surges past 300,000, but more data emerge suggesting omicron is less dangerous MarketWatch
10:20AM	Ocugen's stock bounces after 'positive' results from COVID-19 vaccine candidate in children as young as 2 years old MarketWatch
09:59AM	Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN (BBV152), COVID-19 Candidate Vaccine, in Children 2 18 YEARS GlobeNewswire
09:01AM	Ocugen Stock Is Essentially Back to Being an Eye Disease Play InvestorPlace
08:33AM	5 Top Stock Gainers for Thursday: Twitter, Ocugen, Vroom TheStreet.com
Dec-29-21 01:03PM	Why Ocugen Stock Is Falling Today Motley Fool -7.20%
Dec-27-21 06:30AM	2 Overpriced Meme Stocks to Avoid in 2022 Motley Fool
Dec-24-21 08:15AM	A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State InvestorPlace
Dec-22-21 12:45PM	Why BioNTech, Novavax, and Ocugen Stocks Are Slipping Today Motley Fool -5.86%
Dec-21-21 02:46PM	Ocugen Stock Is Down but Not Out InvestorPlace +5.61%
Dec-20-21 05:21PM	Top Biotech Stocks for Q1 2022 Investopedia
04:32PM	Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:34AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday InvestorPlace
Dec-19-21 06:00AM	Better Buy: Ocugen vs. Pfizer Motley Fool
Dec-18-21 08:15AM	Ocugen Inc (OCGN) CEO Shankar Musunuri Sold $600,300 of Shares GuruFocus.com
Dec-16-21 03:39PM	Ocugens Covid-19 Vaccine Might Have One up on mRNA Vaccines TipRanks -7.38%
Dec-15-21 03:48PM	Why Ocugen Stock Jumped Today Motley Fool +12.68%
01:52PM	As Covaxin Catalyst Fades, Stay Away From Ocugen Stock InvestorPlace
01:08PM	Christmas Is a Time for Ocugen Shareholders to Give Thanks InvestorPlace
10:34AM	Ocugen Partnered COVID-19 Vaccine Candidate Generates Immune Memory At Least 6 Months After Vaccination Benzinga
06:46AM	New Data Suggest COVAXIN (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination GlobeNewswire
02:58AM	Eli Lilly, Ocugen, UPS Rise Premarket; Domino's Pizza Falls Investing.com
02:28AM	Ocugen Surges on Claim Covid Vaccine May Protect Against Variants Investing.com
Dec-13-21 07:37AM	Better Buy: Ocugen vs. Novavax Motley Fool
Dec-11-21 07:55AM	How Worrisome Is Ocugen's Latest Bad News? Motley Fool
Dec-09-21 12:19PM	Investor Fears About Covaxin Have Ocugen Shares on Sale InvestorPlace -6.30%
07:28AM	Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration GlobeNewswire
Dec-06-21 01:45PM	Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today Motley Fool -6.25%
12:01PM	Ocugen Investors Are Betting On a Horse Than Cant Win the Race InvestorPlace
Dec-04-21 04:39PM	Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November Motley Fool
Nov-30-21 02:36PM	Ocugen: IND Halt Not a Concern for Covaxin, Says Analyst TipRanks
01:06PM	FDA places a hold on Ocugen's plan for U.S. trials of the Covid-19 vaccine Covaxin American City Business Journals
06:30AM	Ocugen Looks Risky as Markets Tire Of Speculative Vaccine Plays InvestorPlace
06:00AM	Ocugen Stock Very Well May Have Bottomed Out Here InvestorPlace
Nov-29-21 04:03PM	Top Small Cap Stocks for December 2021 Investopedia
Nov-26-21 07:01AM	Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN (BBV152) GlobeNewswire -9.15%
Nov-25-21 08:00AM	3 Small-Cap COVID Stocks With Huge Upside Motley Fool
Nov-24-21 02:57PM	Think Twice Before You Roll the Dice on Ocugen Stock InvestorPlace
07:00AM	Better Buy: Ocugen or Novavax? Motley Fool
Nov-22-21 07:32AM	7 Stocks to Sell Before They Head to the Market Graveyard InvestorPlace
Nov-21-21 08:04AM	Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen Motley Fool
Nov-20-21 06:40AM	Ocugen Stock: Bull vs. Bear Motley Fool
Nov-19-21 06:17PM	Why Ocugen Shot 8% Higher on Friday Motley Fool +6.34%
02:12PM	The Slide in Ocugen Could Be a Slide to a Homerun InvestorPlace
Nov-18-21 04:03PM	Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.10%
07:30AM	Why This Meme Stock Isn't Worth the Trouble Motley Fool
06:04AM	3 Biotech Stocks That Have More Than Tripled so far This Year Motley Fool
Nov-17-21 06:30AM	3 Things About Ocugen That Smart Investors Know Motley Fool -5.90%
06:00AM	Ocugen Proves Groupthink Is a Double-Edged Sword InvestorPlace
Nov-16-21 03:18PM	Ocugen Needs More Than Covaxin to Boost Its Falling Shares InvestorPlace
10:49AM	As OCGN Stock Trudges Along Without Real Hope Must Wane InvestorPlace
Nov-12-21 11:58AM	Ocugen: What You Need to Know Right Now TipRanks
06:03AM	Here's What Needs to Happen for Ocugen Stock to Be a Screaming Buy Motley Fool
06:00AM	Is Ocugen About to Beat Moderna in This One Market? Motley Fool
Nov-11-21 01:34PM	WHOs Nod Cant Mask Ocugens Flimsy Fundamentals InvestorPlace
Nov-10-21 05:52AM	Does Ocugen Have a Shot at Winning EUA for Its COVID Vaccine in Kids? Motley Fool
Nov-09-21 05:30PM	Ocugen, Inc. (OCGN) Q3 2021 Earnings Call Transcript Motley Fool -7.37%
10:00AM	Sell-the-News Moment Is Your Chance to Reload on Ocugen InvestorPlace
07:30AM	Ocugen Provides Business Update and Third Quarter 2021 Financial Results GlobeNewswire
Nov-08-21 09:24AM	Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration GlobeNewswire -5.96%
08:22AM	Ocugen Seeks FDA Nod for Trial of Its Retinal Degeneration Treatment Investing.com
06:45AM	Where Will Ocugen Be in 3 Years? Motley Fool
06:00AM	Ocugen Stock Looks Poised to Take a Tumble Right Here InvestorPlace
Nov-07-21 06:20AM	Is Ocugen a Buy? Motley Fool
Nov-05-21 01:37PM	Ocugen Seeks FDA Emergency Use Nod For Covaxin COVID-19 Vaccine In Kids Benzinga
12:38PM	With Ocugen Stock: Follow The Lead of Traders and Sell The News InvestorPlace
11:10AM	Ocugen applies for emergency FDA authorization for use of its Covid-19 vaccine in children American City Business Journals
09:42AM	Here's Why Shares of Moderna, Novavax, and Ocugen Have All Been Extremely Volatile This Week Motley Fool
07:55AM	This Surprising FDA Announcement Could Be Huge for Ocugen Motley Fool
06:38AM	Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN (BBV152) for Children Ages 2-18 Years GlobeNewswire
06:02AM	Is Ocugen's Surge Much Ado About Nothing? Motley Fool
Nov-04-21 04:25PM	Avoid Ocugen The Vaccine Is Too Little, Too Late InvestorPlace -20.97%
07:25AM	4 Stocks Insiders Are Selling Benzinga
Nov-03-21 02:45PM	Ocugen Neared $16 Yesterday, But Ill Eat 4 Hats If It Gets to $32 InvestorPlace -18.76%

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kumar Ramesh	Director	Jan 18	Option Exercise	0.51	7,500	3,825	7,500	Jan 20 04:33 PM
Kumar Ramesh	Director	Jan 18	Sale	4.07	7,500	30,525	0	Jan 20 04:33 PM
Potti Manish	Director	Dec 16	Option Exercise	1.43	45,000	64,530	45,000	Dec 17 09:24 PM
Musunuri Shankar	Chief Executive Officer	Dec 16	Sale	5.22	115,000	600,300	1,145,299	Dec 17 09:23 PM
Musunuri Shankar	Chief Executive Officer	Nov 16	Sale	8.04	115,000	924,600	1,260,299	Nov 18 04:07 PM
Zhang Junge	Director	Nov 03	Sale	17.32	150,300	2,603,196	731,431	Nov 05 04:06 PM
Kompella Uday	Director	Nov 02	Sale	16.01	25,000	400,250	154,416	Nov 03 07:38 PM
Potti Manish	Director	Nov 02	Sale	15.07	63,429	955,875	27,695	Nov 03 07:36 PM
Castillo Kirsten	Director	Nov 02	Sale	15.00	15,000	225,000	50,000	Nov 03 07:35 PM
Zhang Junge	Director	Nov 02	Sale	15.75	149,700	2,357,775	881,731	Nov 03 07:34 PM
Musunuri Shankar	Chief Executive Officer	Nov 01	Option Exercise	0.51	115,367	58,837	521,367	Nov 03 07:38 PM
Kompella Uday	Director	Nov 01	Sale	14.05	25,000	351,250	179,416	Nov 03 07:38 PM
Musunuri Shankar	Chief Executive Officer	Nov 01	Sale	14.15	115,367	1,632,443	406,000	Nov 03 07:38 PM
Subramanian Sanjay	Chief Financial Officer	Oct 26	Sale	11.07	10,000	110,700	35,591	Oct 27 05:09 PM
Kompella Uday	Director	Oct 26	Sale	12.05	25,000	301,250	204,416	Oct 27 04:55 PM
Kompella Uday	Director	Oct 25	Sale	9.08	46,371	421,049	229,416	Oct 27 04:55 PM
Kompella Uday	Director	Oct 21	Sale	9.01	1,898	17,101	275,787	Oct 22 07:58 PM
Kompella Uday	Director	Oct 20	Sale	9.02	1,731	15,614	277,685	Oct 20 06:57 PM
Kumar Ramesh	Director	Oct 18	Option Exercise	0.51	7,500	3,825	7,500	Oct 20 06:56 PM
Kompella Uday	Director	Oct 18	Sale	8.41	200,000	1,682,000	279,416	Oct 20 06:57 PM
Kumar Ramesh	Director	Oct 18	Sale	8.13	7,500	60,975	0	Oct 20 06:56 PM
Musunuri Shankar	Chief Executive Officer	Oct 15	Option Exercise	0.33	125,000	41,250	531,000	Oct 15 04:02 PM
Subramanian Sanjay	Chief Financial Officer	Oct 15	Option Exercise	2.19	7,990	17,498	53,581	Oct 15 04:01 PM
Subramanian Sanjay	Chief Financial Officer	Oct 15	Sale	9.96	7,990	79,580	45,591	Oct 15 04:01 PM
Musunuri Shankar	Chief Executive Officer	Oct 15	Sale	9.80	125,000	1,225,000	406,000	Oct 15 04:02 PM
Musunuri Shankar	Chief Executive Officer	Sep 15	Option Exercise	0.33	125,000	41,250	531,000	Sep 17 04:01 PM
Musunuri Shankar	Chief Executive Officer	Sep 15	Sale	7.52	125,000	940,000	406,000	Sep 17 04:01 PM
Subramanian Sanjay	Chief Financial Officer	Aug 16	Option Exercise	0.34	30,000	10,200	75,591	Aug 18 04:01 PM
Subramanian Sanjay	Chief Financial Officer	Aug 16	Sale	7.22	30,000	216,600	45,591	Aug 18 04:01 PM
Kompella Uday	Director	Jul 30	Option Exercise	1.83	10,000	18,300	560,674	Jul 30 05:28 PM
Kompella Uday	Director	Jul 30	Sale	6.81	10,000	68,072	550,674	Jul 30 05:28 PM
Kumar Ramesh	Director	Jul 19	Option Exercise	0.51	7,500	3,825	7,500	Jul 21 04:04 PM
Kumar Ramesh	Director	Jul 19	Sale	6.40	7,500	48,000	0	Jul 21 04:04 PM
Subramanian Sanjay	Chief Financial Officer	Jul 15	Option Exercise	0.34	31,086	10,569	76,677	Jul 16 04:01 PM
Subramanian Sanjay	Chief Financial Officer	Jul 15	Sale	6.70	31,086	208,276	45,591	Jul 16 04:01 PM
Kompella Uday	Director	Jun 25	Option Exercise	1.83	10,000	18,300	560,674	Jun 25 04:17 PM
Kompella Uday	Director	Jun 25	Sale	8.13	10,000	81,345	550,674	Jun 25 04:17 PM
Subramanian Sanjay	Chief Financial Officer	Jun 15	Option Exercise	0.34	31,000	10,540	76,591	Jun 17 05:25 PM
Subramanian Sanjay	Chief Financial Officer	Jun 15	Sale	7.00	31,000	217,000	45,591	Jun 17 05:25 PM
Potti Manish	Director	Jun 15	Sale	8.86	68,185	604,119	91,124	Jun 17 05:23 PM
Musunuri Shankar	Chief Executive Officer	Jun 08	Option Exercise	0.33	22,800	7,524	428,800	Jun 09 07:22 PM
Musunuri Shankar	Chief Executive Officer	Jun 08	Sale	10.98	22,800	250,344	406,000	Jun 09 07:22 PM
Musunuri Shankar	Chief Executive Officer	Jun 07	Option Exercise	0.33	7,758	2,560	413,758	Jun 09 07:22 PM
Musunuri Shankar	Chief Executive Officer	Jun 07	Sale	10.94	7,758	84,873	406,000	Jun 09 07:22 PM
Castillo Kirsten	Director	Jun 07	Sale	10.00	10,000	100,000	65,000	Jun 09 07:21 PM
Kompella Uday	Director	May 28	Option Exercise	1.88	7,191	13,519	557,865	Jun 01 06:10 AM
Kompella Uday	Director	May 28	Sale	8.82	7,191	63,417	550,674	Jun 01 06:10 AM
Fernandes Prabhavathi	Director	May 25	Option Exercise	0.93	33,500	31,080	19,500	May 27 04:07 PM
Fernandes Prabhavathi	Director	May 25	Sale	8.20	33,500	274,755	0	May 27 04:07 PM
Subramanian Sanjay	Chief Financial Officer	May 14	Option Exercise	0.34	31,000	10,540	76,591	May 14 04:58 PM
Subramanian Sanjay	Chief Financial Officer	May 14	Sale	8.18	31,000	253,673	45,591	May 14 04:58 PM
Tammara Vijay	Senior Vice President	May 04	Option Exercise	0.81	15,711	12,755	6,500	May 05 08:15 PM
Tammara Vijay	Senior Vice President	May 04	Sale	13.68	15,711	214,954	0	May 05 08:15 PM
Tammara Vijay	Senior Vice President	May 03	Option Exercise	0.46	4,317	1,986	4,317	May 03 08:53 PM
Musunuri Shankar	Chief Executive Officer	May 03	Option Exercise	0.51	195,809	99,863	601,809	May 03 09:00 PM
Kompella Uday	Director	May 03	Sale	15.01	50,000	750,500	550,674	May 03 09:05 PM
Musunuri Shankar	Chief Executive Officer	May 03	Sale	14.24	195,809	2,788,320	406,000	May 03 09:00 PM
Tammara Vijay	Senior Vice President	May 03	Sale	16.00	4,317	69,072	0	May 03 08:53 PM
Potti Manish	Director	May 03	Sale	15.02	60,000	901,200	63,429	May 05 08:13 PM
Potti Manish	Director	May 03	Sale	15.01	28,000	420,280	0	May 05 08:13 PM
Kompella Uday	Director	Apr 30	Option Exercise	0.51	20,000	10,200	620,674	May 03 09:05 PM
Kompella Uday	Director	Apr 30	Sale	11.56	20,000	231,200	600,674	May 03 09:05 PM
Tammara Vijay	Senior Vice President	Apr 29	Option Exercise	0.75	29,991	22,442	12,880	May 03 08:53 PM
Subramanian Sanjay	Chief Financial Officer	Apr 29	Option Exercise	2.19	7,990	17,498	53,581	May 03 09:06 PM
Subramanian Sanjay	Chief Financial Officer	Apr 29	Sale	10.98	7,990	87,730	45,591	May 03 09:06 PM
Tammara Vijay	Senior Vice President	Apr 29	Sale	10.97	29,991	328,881	0	May 03 08:53 PM
Kompella Uday	Director	Apr 26	Sale	11.70	350,000	4,095,000	600,674	Apr 28 06:52 PM
Kumar Ramesh	Director	Apr 19	Option Exercise	0.51	7,500	3,825	7,500	Apr 21 04:16 PM
Kumar Ramesh	Director	Apr 19	Sale	5.33	7,500	39,975	0	Apr 21 04:16 PM
Potti Manish	Director	Mar 05	Option Exercise	0.84	28,000	23,520	28,000	Mar 08 08:38 PM
Subramanian Sanjay	Chief Financial Officer	Jan 29	Option Exercise	0.51	35,591	18,151	45,591	Feb 01 05:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience